Guangdong Winstar

Founded in October 2013, Guangdong Winstar Medical Technology Co., Ltd. is a leading provider of medical equipment for OCT (optical interferometry tomography). Its main business focus on the R&D, production and sales of intraluminal OCT imaging diagnostic medical devices, with a registered capital of 27.78 million RMB and the legal representative is Mr. Li Bailing.

In 2014, Guangdong Winstar acquired all the tangible and intangible assets of Tomophase Corporation, a manufacturer of OCT equipment in the United States. At that time, Mr. Hu Chunhua, secretary of Guangdong Provincial Party Committee, witnessed the signing ceremony of Winstar's acquisition of Tomphase in the United States. The company now owns total 85 independent intellectual property rights and has obtained the Guangdong Provincial High-tech Product Certificate (Yue Gao Qi Xie 2016 -1). According to the novelty search report by Guangdong Scientific and Technical Information Institute (No. 20155695, A2016237, A2017048, A2017236, A2017237 & A2017238) shows that the company's products are currently the world's leading OCT technology applied in the area of Respiratory, reproductive and gastrointestinal tracts. The University of Heidelberg, Germany used our OCT device and published SCI paper (3 July 2015 Cystic Fibrosis) on respiratory tract. In addition, our equipment has also been approved by the Hong Kong Innovation and Technology Bureau (Application of OCT technology in the diagnosis of uterine diseases, No. ITS/376/15FX) , and by Guangdong Provincial Department of Science and Technology (Research and Development of Practical OCT Respiratory System and its clinical application Research, No. 2014A020215036).

The company's product has obtained FDA approval of USA(510K No. K102599), and the product has obtained the Qualified inspection report from the National Medical Device Inspection Institute, and have obtained the Innovative product approval by the National Food & Drug Administration Bureau (No. 2015144). Winstar is expected to obtain the first CFDA certification of OCT device in the respiratory tract within 2018.